StreetAlpha.app
Home › Stocks › MGTX

MeiraGTx Holdings plc (MGTX)

$8.46
▼ −3.20%
LAST CLOSE · NOV 17

MeiraGTx develops genetic medicines and manufactures them at its own sites in the United Kingdom and Ireland. It last closed at $8.46 on Nov 17, down 3.20% on the day.

AI Auto Pilots
Is MGTX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$401.9M
+1365.9% vs a year ago
Net income
$78.3M
19.5% margin
EPS (diluted)
$0.87
Free cash flow
−$3.0M
−0.7% margin
Valuation
Market cap
$826.8M
97.7M shares
P/E
9.7
Price over 12 month EPS
Price to sales
2.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$184.7M
At Sep 30
Debt
$121.9M
At Sep 30
Shares outstanding
97.7M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $37.7M$37.7MFY2021FY2022: $15.9M$15.9MFY2022FY2023: $14.0M$14.0MFY2023FY2024: $33.3M$33.3MFY2024FY2025: $81.4M$81.4MFY2025

From MGTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Hold
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Hold
1firm
0 Buy1 Hold0 Sell
Only 1 firm rated MGTX in the past 90 days, not enough for a consensus
Average 12-month target
$16.00
▲ 89.1% upside

Based on 1 analyst who set a price target on MGTX in the past 90 days. The average target is $16.00, with a high of $16.00 and a low of $16.00, compared with the last close of $8.46.

Low $16.00Avg $16.00High $16.00
Blue marker: last close $8.46
Highest target$16.00
Average target$16.00
Lowest target$16.00
Latest rating changes
Goldman SachsInitiated
Sep 24Hold$16
RBC CapitalTarget raised
Aug 14Buy$26 → $27
RBC CapitalMaintained
Jul 8Buy$26
HC Wainwright & Co.Reiterated
Jul 8Buy$20
DateFirmActionRatingPrice target
Sep 24Goldman SachsInitiatedHold$16
Aug 14RBC CapitalTarget raisedBuy$26 → $27
Jul 8RBC CapitalMaintainedBuy$26
Jul 8HC Wainwright & Co.ReiteratedBuy$20
Loading…

Technical Analysis

MGTX · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 10% below its 20 day and 24% below its 50 day average. It is 23% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 37), near oversold. The nearest support is the swing low (Nov 6) at $8.44, and the nearest resistance the Pivot at $8.47.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityNormal, 6.4%/day
Key levels
$15.3552 week high+81.4%
$11.86100 day average+40.2%
$10.5150 day average+24.2%
$10.39200 day average+22.8%
$9.75Swing high (Nov 11)+15.2%
$9.3020 day average+9.9%
$8.66Pivot R1+2.4%
$8.47Pivot+0.1%
$8.46Last close
$8.44Swing low (Nov 6)−0.2%
$8.27Pivot S1−2.2%
$6.6252 week low−21.7%
Indicators
RSI (14)37.17Weak, oversold below 30Neutral
MACD-0.45Above its signal lineBullish
Stochastic25.8Middle of its rangeNeutral
ADX (14)29.1Trending down
Williams %R-89.7Oversold below −80, overbought above −20Oversold
CCI (20)-185.3Oversold below −100, overbought above 100Oversold
Rate of change−11.1%Change over 10 sessionsBearish
ATR (14)$0.55Typical daily range, 6.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for MGTX

What happened before

See how MGTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow MGTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How MGTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in MGTX in the last 90 days.

Loading…

See today’s whale options flow across the market →

MGTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲98 buying vs 55 selling
  • ▲Held by funds +4.1 pts
  • ▲Funds holding +19
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding176157+12.1%
In funds' top 10660.0%
Held by funds85.1%81.0%+4.1 pts
New / increased37 / 6138 / 80−16.9%
Reduced / sold out34 / 2122 / 12+61.8%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MGTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MGTX is in one of them and how their past MGTX trades turned out.

MGTX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MGTX in an article yet. Here's the latest on the wider market.

About MeiraGTx Holdings

MeiraGTx develops genetic medicines for inherited conditions and more common diseases, including conditions affecting the eye, salivary gland and central nervous system. The company makes its own viral vectors, plasmid DNA and quality control testing at manufacturing sites in London, United Kingdom and Shannon, Ireland. It is also developing a platform that uses oral small molecules to control gene expression in the body. Its headquarters are in New York, and it supplies commercial manufacturing to Johnson & Johnson Innovative Medicine.

Headquarters
New York, NY